N/A N=14 Targeted High-definition Transcranial Direct Current Stimulation (HD-tDCS) for Reducing Post-stroke Movement Impairments
Stroke
Primary: Fugl-Meyer Upper Extremity Assessment Part A — 4.13; 5.38; 0.88 score on a scale — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=76 Cognitive Behavioral Therapy to Increase CPAP Adherence in Veterans With PTSD
Obstructive Sleep Apnea · PTSD · Posttraumatic Stress Disorder
Primary: Time in Minutes of "mask-on" Positive Airway Pressure (PAP) Machine Usage Per Night — 234.00; 144.25; 157.04; 152.39 minutes per night — p=0.027
Phase 4 N=120 Sugammadex To IMprove Bowel Function
Bowel Dysfunction · Postoperative Complications · Neuromuscular Blockade
Primary: Gastric Emptying — 1120; 1130 log(ng*ml-1)*min — p=0.58
Phase 1 N=19 Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
Advanced Solid Tumor
Primary: Number of Patients Who Developed Does-limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Phase 3 N=421 The Healthy Patterns Sleep Study
Dementia · Alzheimer Disease · Circadian Rhythm Disorders
Primary: Change in the Quality of Life in Alzheimer's Disease (QOL-AD) Scale — 0.56; -0.47 scores on a scale
N/A N=25 Exploratory Study on Effect of Whitening Agent With Emulsion Gel in Xerostomic Population
Xerostomia
Primary: Subjective Perception of Mouth Dryness — 6.92; 6.46; 4.21; 3.46 units on a scale — p=.45
N/A N=74 Parenting Strength At Home- Parents Pilot
Parenting Behaviors and PTSD Symptoms
Primary: Client Satisfaction Questionnaire-8 (CSQ; Attkisson & Greenfield, 2004) — 29.9 score on a scale
Phase 3 N=214 Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
HER2-positive Breast Cancer
Primary: Breast Pathological Complete Response (bpCR) — 71; 73 Participants — p=0.54
Phase 1 N=18 Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Multiple Myeloma
Primary: Absence of Dose Limiting Toxicity — 3; 1; 3; 9 Participants
N/A N=183 Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
Type 1 Diabetes
Primary: Severe Hypoglycemia — 0; 3 events
N/A N=220 Edwards PASCAL Transcatheter Valve Repair System Registry
Mitral Valve Insufficiency
Primary: Major Adverse Events (MAEs) — 9; 2; 0; 1 Participants
Phase 1 N=12 A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Rosuvastatin — 2.178; 2.625 nanogram per milliliter (ng/mL)
Phase 2 N=6 Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
Resectable Esophageal Cancer · GastroEsophageal Cancer
Primary: Number of Participants With Dose Limiting Toxicity — 0 Participants
N/A N=60 Service Dog Training Program for Military Veterans With PTSD
Post Traumatic Stress Disorder
Primary: Post Traumatic Stress Symptom Severity — 43.7; 38.9; 35.1; 31.6 score on a scale
Phase 3 N=930 Zoliflodacin in Uncomplicated Gonorrhoea
Gonorrhea
Primary: Microbiological Cure Rate for Zoliflodacin Compared to a Combination of a Single Dose of Ceftriaxone and Azithromycin. — 90.9; 96.2 percentage of participants